A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system

Thrombosis and Haemostasis

Volumn 114, Issue 6, 2015, Pages 1290-1298

  Villines, Todd C ^a   Schnee, Janet ^b   Fraeman, Kathy ^c   Siu, Kimberly ^b   Reynolds, Matthew W ^c   Collins, Jenna ^c   Schwartzman, Eric ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c EVIDERA   (United States)

^d NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

Author keywords

Anticoagulant; Atrial fibrillation; Bleeding; Stroke; Stroke prevention

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COHORT ANALYSIS; DEMOGRAPHY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON VALVULAR ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT; STATISTICAL ANALYSIS; THROMBOSIS; ADOLESCENT; ADULT; BLOOD; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CHEMICALLY INDUCED; COMORBIDITY; COMPARATIVE STUDY; COMPLICATION; DISEASE FREE SURVIVAL; DRUG SCREENING; FACTUAL DATABASE; HEMORRHAGE; INSURANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SOLDIER; STROKE; THROMBOPHILIA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; COMORBIDITY; DABIGATRAN; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INSURANCE COVERAGE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MILITARY PERSONNEL; MORTALITY; MYOCARDIAL INFARCTION; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; THROMBOPHILIA; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84983096272     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-06-0453     Document Type: Article

References (27)

1. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005; 36: 1776-1781.
2. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98: 476-484.
3. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U. S. adult population. Am J Cardiol 2013; 112: 1142-1147.
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
5. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003; 41: 1633-1652.
6. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76.
7. Aguilar MI, Kuo RS, Freeman WD. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation. Neurol Clin 2013; 31: 659-675.
8. Stassen J RK, Zimmerman R, et al. Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR 954 ZW in healthy subjects. XVIII Congress of the International Society on Thrombosis and Haemostasis. Paris, France. July 6-12, 2001. Thromb Haemost 2001; Abstract OC2347.
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
10. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011; 10: 150-161.
11. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013; 6: 567-574.
12. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? J Am Med Assoc 2003; 290: 2685-2692.
13. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015; 131: 157-164.
14. Bergman E, Smith JG, Wieloch M, et al. Dabigatran in clinical practice--oneyear experience at Skane University Hospital. Thromb Res 2013; 132: 316-317.
15. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world“ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
16. Michel J, Mundell D, Boga T, et al. Dabigatran for anticoagulation in atrial fibrillation-early clinical experience in a hospital population and comparison to trial data. Heart Lung Circ 2013; 22: 50-55.
17. Schoof N, Schnee J, Schneider G, et al. Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin 2014; 30: 795-804.
18. Schulman S, Shortt B, Robinson M, et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013; 11: 1295-1299.
19. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014; 167: 810-817.
20. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
21. Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc 2013; 2: e000535.
22. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014; 127: 650-656 e5.
23. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. Br Med J Open 2013; 3: pii: e002758..
24. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
25. Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 2015; 132: 194-204.
26. Douxfils J, Buckinx F, Mullier F, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2014; 3: e000515.
27. Artang R, Rome E, Nielsen JD, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 2013; 112: 1973-1979.